Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus infection in South Africa

We developed a decision-analytic model that assessed the cost-effectiveness of three possible HBV PMTCT approaches in pregnancy; <b>S1</b>: no PMTCT intervention; <b>S2:</b>screening and antiviral prophylaxis for all women who test HBsAg-positive; <b>S3</b>: screening of all women for HBsAg, followed by HBeAg testing and antiviral prophylaxis for women who are HBsAg-positive and HBeAg-positive. We compared use of standard laboratory assays with a point of care test for HBsAg. Our outcome was cost per HBV infection avoided and the analysis followed a healthcare perspective.We populated our model with data from South Africa.